Results 171 to 180 of about 121,797 (299)
SkinSensPred as a Promising in Silico Tool for Integrated Testing Strategy on Skin Sensitization. [PDF]
Wang SS, Wang CC, Tung CW.
europepmc +1 more source
The use of MHC class I or class II 'knock out' mice to investigate the role of these antigens in allosensitization [PDF]
Demetris, AJ +10 more
core
Objective We employed global genetic deletion of CD14 and intra‐articular CD14 blockade across multiple murine osteoarthritis (OA) models that vary in severity of pathology and rate of progression to test the hypothesis that CD14 inhibition attenuates synovial inflammation and associated pain during disease progression.
Kevin G. Burt +18 more
wiley +1 more source
Application of Defined Approaches for Skin Sensitization to Agrochemical Products. [PDF]
Strickland J +11 more
europepmc +1 more source
Objective Still disease represents a prototypical polygenic systemic autoinflammatory disease, characterized by recurrent systemic inflammation and dysregulation of innate immunity. Despite extensive clinical characterization, familial clustering Still disease remains unreported.
Longfang Chen +23 more
wiley +1 more source
Skin Sensitization Testing Using New Approach Methodologies. [PDF]
Strickland J.
europepmc +1 more source
Objective Nerve growth factor (NGF), a key mediator of pain, is increased in osteoarthritic (OA) joints. Antibodies against NGF show analgesic effects in painful knee OA, but clinical development was stopped because of side effects in the joints. Knowledge about the biologic effects of NGF on joint tissues is limited. Therefore, we explored the effects
Alia M. Obeidat +14 more
wiley +1 more source
Pseudopterosin A-D Modulates Dendritic Cell Activation in Skin Sensitization. [PDF]
Hölken JM +3 more
europepmc +1 more source
Prevalence of skin sensitization and dermatitis among epoxy-exposed workers in the wind turbine industry. [PDF]
Christiansen AG +8 more
europepmc +1 more source
Navigating adverse immunostimulation: A practical guide for clinical researchers
Problem Setting As drug development moves towards more complex products, early clinical development programmes are increasingly hampered by unwanted and/or unexpected activation of the immune system (adverse immune stimulation, AIS). Solution At the Centre for Human Drug Research, we have introduced standardized procedures to make AIS manageable, while
Juliette A. van den Noort +3 more
wiley +1 more source

